EU may consider deal on Merck’s COVID pill after approval procedure begins – source

Published by

By Francesco Guarascio (Reuters) – The European Union may consider signing a supply deal with U.S. drugmaker Merck for its experimental COVID-19 pill, but only after the company starts the process of seeking approval for the drug in the bloc, a senior EU official said on Tuesday. The oral antiviral treatment molnupiravir has been developed with Ridgeback Biotherapeutics. On Monday Merck applied for emergency use authorisation in the United States, which has already secured 1.7 million courses of molnupiravir at a price of $700 per course. The EU would consider a joint procurement of molnupirav…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *